New York, January 13, 2014 / Accesswire / - Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Medbox Inc (OTCMKTS:MDBX), GreenGro Technologies, Inc. (OTCMKTS:GRNH).
GW Pharmaceuticals PLC- ADR's (NASDAQ:GWPH) shares continued to move higher and added another 2% after soaring 25% in past two trading sessions. The company announces the pricing of its follow-on offering of American Depositary Shares, or ADSs, on the NASDAQ Global Market. GW will issue 2,441,110 ADSs on the NASDAQ Global Market at a price of $36.00 per ADS raising gross proceeds of $87.9 million (before deducting underwriting discount, commissions and offering expenses). GW has also granted the underwriters a 30-day option to purchase up to an additional 366,165 ADSs at the offering price. Closing of the offering is expected to occur on January 14, 2014.
Free Urgent Insider Catalyst Report For GWPH Available Here: http://marketbuzzreport.com/index.php?code=GWPH (Or Copy and paste the URL into your browser)
Medbox Inc (OTCMKTS:MDBX) climbed up 23% to $41.69 on hefty volume of 216K shares in first hour of trading. Last week, the company announced it has improved on its products for use in recreational and medical marijuana facilities. Company executives discussed the many improvements to the Medbox machines, which shall soon be marketed as a "safe" that dispenses medicine.
Free Urgent Insider Catalyst Report For MDBX Available Here: http://marketbuzzreport.com/index.php?code=MDBX (Or Copy and paste the URL into your browser)
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares are -30% on what appears to be light volume after the stock skyrocketed 516% on Thursday and Friday following news that a trial for the company's (ICPT) beticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was stopped early due to high efficacy. Intercept believes that an increase of "bad" cholesterol and decrease of "good" cholesterol in patients will probably be similar to results reported in 2009 regarding a trial of diabetic patients with nonalcoholic fatty liver disease. The efficacy, safety and tolerability profile of OCA was the basis for the drug's selection for treating NASH. There is also preclinical evidence that OCA may be "able to shunt excess lipids away from collecting in arteries and other organs, which could also be beneficial," Intercept says.
Free Urgent Insider Catalyst Report For ICPT Available Here: http://marketbuzzreport.com/index.php?code=ICPT (Or Copy and paste the URL into your browser)
GreenGro Technologies, Inc. (OTCMKTS:GRNH) added 52% to $0.34 on very unusual volume of 16 million shares. The company announces its client has obtained the long awaited approval from regulatory officials in Arizona for a significant marijuana cultivation project. This zoning approval paves the way for final design implementation of contracts as well as maintenance agreements.
Also based in Phoenix, DreamBrands has assembled a team of specialists including chemists, scientists, formulators, food technologists, engineers, designers and marketers.
Free Urgent Insider Catalyst Report For GRNH Available Here: http://marketbuzzreport.com/index.php?code=GRNH (Or Copy and paste the URL into your browser)
USMarketBuzz.com is an investment community that focuses on MicroCap Securities. USMarketBuzz.com is an authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit http://www.USMarketBuzz.com/ for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.USMarketBuzz.com/. Follow us on Facebook: https://www.facebook.com/usmarket.buzz Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126 (SMS alerts are free, however data rates may apply, check your wireless plan for details.).